Amgen-Beta JV Significant For China Medical Industry, Execs Say
This article was originally published in PharmAsia News
Executive Summary
Amgen-Beta Pharma, the joint venture formed recently by Beta Pharma and Amgen is far more ambitious than its initial focus on getting Vectibix (panitumumab) for colon cancer on China's market, company officials said.